Nadia Harbeck

Deutsches Archäologisches Institut, Zentrale (DE)

Research Areas

Discover Papers by Nadia Harbeck

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

131

Publications

2055

Citations

85275

i10-index

613

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Pembrolizumab for Early Triple-Negative Breast Can...	2020	2957
Palbociclib and Letrozole in Advanced Breast Cance...	2016	2887
Breast cancer	2019	2845
Trastuzumab Deruxtecan in Previously Treated HER2-...	2022	2409
Breast cancer	2016	2265
3rd ESO–ESMO International Consensus Guidelines fo...	2016	2060
Tailoring therapies—improving the management of ea...	2015	1822
Fulvestrant plus palbociclib versus fulvestrant pl...	2016	1800
Pembrolizumab plus chemotherapy versus placebo plu...	2020	1746
Palbociclib in Hormone-Receptor–Positive Advanced ...	2015	1571

Publications

1.
Pembrolizumab for Early Triple-Negative Breast Cancer
Year: 2020Citations: 2957DOI: 10.1056/nejmoa1910549
2.
Palbociclib and Letrozole in Advanced Breast Cancer
Year: 2016Citations: 2887DOI: 10.1056/nejmoa1607303
3.
Breast cancer
Year: 2019Citations: 2845DOI: 10.1038/s41572-019-0111-2
4.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Year: 2022Citations: 2409DOI: 10.1056/nejmoa2203690
5.
Breast cancer
Year: 2016Citations: 2265DOI: 10.1016/s0140-6736(16)31891-8
6.
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Year: 2016Citations: 2060DOI: 10.1093/annonc/mdw544
7.
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Year: 2015Citations: 1822DOI: 10.1093/annonc/mdv221
8.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Year: 2016Citations: 1800DOI: 10.1016/s1470-2045(15)00613-0
9.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Year: 2020Citations: 1746DOI: 10.1016/s0140-6736(20)32531-9
10.
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Year: 2015Citations: 1571DOI: 10.1056/nejmoa1505270

About Nadia Harbeck

Nadia Harbeck is a researcher with 2055 publications and 85275 citations. They are affiliated with Deutsches Archäologisches Institut, Zentrale. Their research focuses on . With an h-index of 131, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Nadia Harbeck and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year